610 related articles for article (PubMed ID: 25220794)
1. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
Danese S; Panés J
Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
[TBL] [Abstract][Full Text] [Related]
2. Anti-integrin therapy for inflammatory bowel disease.
Park SC; Jeen YT
World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
[TBL] [Abstract][Full Text] [Related]
3. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
Panés J; Salas A
J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
[TBL] [Abstract][Full Text] [Related]
4. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
Rivera-Nieves J
Curr Opin Gastroenterol; 2015 Nov; 31(6):441-8. PubMed ID: 26398681
[TBL] [Abstract][Full Text] [Related]
5. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
Sands BE
Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349
[TBL] [Abstract][Full Text] [Related]
6. New drugs on the horizon for IBD.
Sands BE
Dig Dis; 2014; 32 Suppl 1():74-81. PubMed ID: 25531356
[TBL] [Abstract][Full Text] [Related]
7. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.
Thomas S; Baumgart DC
Inflammopharmacology; 2012 Feb; 20(1):1-18. PubMed ID: 22205271
[TBL] [Abstract][Full Text] [Related]
8. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
Lamb CA; O'Byrne S; Keir ME; Butcher EC
J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
[TBL] [Abstract][Full Text] [Related]
9. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases.
Saruta M; Papadakis KA
Gastroenterol Clin North Am; 2014 Sep; 43(3):581-601. PubMed ID: 25110260
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Therapeutics for IBD.
Löwenberg M; D'Haens G
Curr Gastroenterol Rep; 2015 Jun; 17(6):21. PubMed ID: 26031830
[TBL] [Abstract][Full Text] [Related]
12. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory pathways of importance for management of inflammatory bowel disease.
Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
[TBL] [Abstract][Full Text] [Related]
14. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update.
Cesarini M; Fiorino G
Expert Rev Clin Immunol; 2013 Apr; 9(4):301-6. PubMed ID: 23557266
[TBL] [Abstract][Full Text] [Related]
15. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S
Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013
[TBL] [Abstract][Full Text] [Related]
16. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation.
Danese S; Semeraro S; Marini M; Roberto I; Armuzzi A; Papa A; Gasbarrini A
Dig Liver Dis; 2005 Nov; 37(11):811-8. PubMed ID: 16168725
[TBL] [Abstract][Full Text] [Related]
17. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
Soler D; Chapman T; Yang LL; Wyant T; Egan R; Fedyk ER
J Pharmacol Exp Ther; 2009 Sep; 330(3):864-75. PubMed ID: 19509315
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.
Ghosh N; Chaki R; Mandal SC
Int Rev Immunol; 2012 Oct; 31(5):410-27. PubMed ID: 23083349
[TBL] [Abstract][Full Text] [Related]
19. Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches.
Abraham BP; Ahmed T; Ali T
Handb Exp Pharmacol; 2017; 239():115-146. PubMed ID: 28233184
[TBL] [Abstract][Full Text] [Related]
20. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.
Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Bamias G; Dulai PS; Boland BS; Sandborn WJ; Patel DR; Rivera-Nieves J
Inflamm Bowel Dis; 2019 Jan; 25(2):270-282. PubMed ID: 30165490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]